Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)GlobeNewsWire • 08/06/25
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/07/25
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.Zacks Investment Research • 04/01/25
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks ResignsInvestors Business Daily • 03/31/25
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding StudyGlobeNewsWire • 03/31/25
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 StudyGlobeNewsWire • 03/30/25
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 02/25/25
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025GlobeNewsWire • 02/12/25
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsGlobeNewsWire • 02/05/25
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsGlobeNewsWire • 12/03/24
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult ProgramsGlobeNewsWire • 11/12/24
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/24
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027Seeking Alpha • 09/08/24
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 09/06/24